Analysts call $310 CSL target price in new report
SYDNEY: Biotech company CSL was upgraded to ‘buy’ by analysts at Citi Group who believe
SYDNEY: Biotech company CSL was upgraded to ‘buy’ by analysts at Citi Group who believe